These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) - A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergology (AeDA). Pfaar O; Klimek L; Hamelmann E; Kleine-Tebbe J; Taube C; Wagenmann M; Werfel T; Brehler R; Novak N; Mülleneisen N; Becker S; Worm M Allergol Select; 2021; 5():140-147. PubMed ID: 33842829 [TBL] [Abstract][Full Text] [Related]
5. COVID-19 Clinical Features and Outcome in Italian Patients Treated with Biological Drugs Targeting Type 2 Inflammation. Sambugaro G; Brambilla E; Costanzo G; Bonato V; Ledda AG; Del Giacco S; Scarpa R; Rattazzi M; Favero E; Cinetto F; Firinu D Life (Basel); 2024 Mar; 14(3):. PubMed ID: 38541703 [TBL] [Abstract][Full Text] [Related]
6. Allergic diseases and immunodeficiencies in children, lessons learnt from COVID-19 pandemic by 2022: A statement from the EAACI-section on pediatrics. Munblit D; Greenhawt M; Brough HA; Pushkareva A; Karimova D; Demidova A; Warner JO; Kalayci O; Sediva A; Untersmayr E; Rodriguez Del Rio P; Vazquez-Ortiz M; Arasi S; Alvaro-Lozano M; Tsabouri S; Galli E; Beken B; Eigenmann PA Pediatr Allergy Immunol; 2022 Oct; 33(10):e13851. PubMed ID: 36282136 [TBL] [Abstract][Full Text] [Related]
7. COVID-19 and Its Impact on Common Diseases in the Allergy Clinics. Kocatürk E; Abrams EM; Maurer M; Mitri J; Oppenheimer J; Vestergaard C; Zein J J Allergy Clin Immunol Pract; 2023 Nov; 11(11):3289-3303. PubMed ID: 37660731 [TBL] [Abstract][Full Text] [Related]
8. Management of Allergic Diseases During COVID-19 Outbreak. Izquierdo-Domínguez A; Rojas-Lechuga MJ; Alobid I Curr Allergy Asthma Rep; 2021 Feb; 21(2):8. PubMed ID: 33560451 [TBL] [Abstract][Full Text] [Related]
9. EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders. Boyman O; Kaegi C; Akdis M; Bavbek S; Bossios A; Chatzipetrou A; Eiwegger T; Firinu D; Harr T; Knol E; Matucci A; Palomares O; Schmidt-Weber C; Simon HU; Steiner UC; Vultaggio A; Akdis CA; Spertini F Allergy; 2015 Jul; 70(7):727-54. PubMed ID: 25819018 [TBL] [Abstract][Full Text] [Related]
10. The effect of allergy and asthma as a comorbidity on the susceptibility and outcomes of COVID-19. Gao YD; Agache I; Akdis M; Nadeau K; Klimek L; Jutel M; Akdis CA Int Immunol; 2022 Mar; 34(4):177-188. PubMed ID: 34788827 [TBL] [Abstract][Full Text] [Related]
11. New biologics for allergic diseases. Manka LA; Wechsler ME Expert Rev Clin Immunol; 2018 Apr; 14(4):285-296. PubMed ID: 29611440 [TBL] [Abstract][Full Text] [Related]
12. Biologicals in atopic disease in pregnancy: An EAACI position paper. Pfaller B; José Yepes-Nuñez J; Agache I; Akdis CA; Alsalamah M; Bavbek S; Bossios A; Boyman O; Chaker A; Chan S; Chatzipetrou A; du Toit G; Jutel M; Kauppi P; Kolios A; Li C; Matucci A; Marson A; Bendien S; Palomares O; Rogala B; Szepfalusi Z; Untersmayr E; Vultaggio A; Eiwegger T Allergy; 2021 Jan; 76(1):71-89. PubMed ID: 32189356 [TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status. Du H; Dong X; Zhang JJ; Cao YY; Akdis M; Huang PQ; Chen HW; Li Y; Liu GH; Akdis CA; Lu XX; Gao YD Allergy; 2021 Feb; 76(2):510-532. PubMed ID: 32524611 [TBL] [Abstract][Full Text] [Related]
14. A compendium answering 150 questions on COVID-19 and SARS-CoV-2. Riggioni C; Comberiati P; Giovannini M; Agache I; Akdis M; Alves-Correia M; Antó JM; Arcolaci A; Azkur AK; Azkur D; Beken B; Boccabella C; Bousquet J; Breiteneder H; Carvalho D; De Las Vecillas L; Diamant Z; Eguiluz-Gracia I; Eiwegger T; Eyerich S; Fokkens W; Gao YD; Hannachi F; Johnston SL; Jutel M; Karavelia A; Klimek L; Moya B; Nadeau KC; O'Hehir R; O'Mahony L; Pfaar O; Sanak M; Schwarze J; Sokolowska M; Torres MJ; van de Veen W; van Zelm MC; Wang Y; Zhang L; Jiménez-Saiz R; Akdis CA Allergy; 2020 Oct; 75(10):2503-2541. PubMed ID: 32535955 [TBL] [Abstract][Full Text] [Related]
15. Management of patients with chronic rhinosinusitis during the COVID-19 pandemic-An EAACI position paper. Klimek L; Jutel M; Bousquet J; Agache I; Akdis CA; Hox V; Gevaert P; Tomazic PV; Rondon C; Cingi C; Toppila-Salmi S; Karavelia A; Bozkurt B; Förster-Ruhrmann U; Becker S; Chaker AM; Wollenberg B; Mösges R; Huppertz T; Hagemann J; Bachert C; Fokkens W Allergy; 2021 Mar; 76(3):677-688. PubMed ID: 33075144 [TBL] [Abstract][Full Text] [Related]
16. Change in Allergy Practice during the COVID-19 Pandemic. Ozturk AB; Baççıoğlu A; Soyer O; Civelek E; Şekerel BE; Bavbek S Int Arch Allergy Immunol; 2021; 182(1):49-52. PubMed ID: 33059353 [TBL] [Abstract][Full Text] [Related]
18. Biologics for atopic diseases: Indication, side effect management, and new developments. Jappe U; Beckert H; Bergmann KC; Gülsen A; Klimek L; Philipp S; Pickert J; Rauber-Ellinghaus MM; Renz H; Taube C; Treudler R; Wagenmann M; Werfel T; Worm M; Zuberbier T Allergol Select; 2021; 5():1-25. PubMed ID: 33426426 [TBL] [Abstract][Full Text] [Related]
19. Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper. Gelincik A; Brockow K; Çelik GE; Doña I; Mayorga C; Romano A; Soyer Ö; Atanaskovic-Markovic M; Barbaud A; Torres MJ Allergy; 2020 Nov; 75(11):2775-2793. PubMed ID: 32511784 [TBL] [Abstract][Full Text] [Related]
20. Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19. Sokolowska M; Rovati GE; Diamant Z; Untersmayr E; Schwarze J; Lukasik Z; Sava F; Angelina A; Palomares O; Akdis CA; O'Mahony L; Jesenak M; Pfaar O; Torres MJ; Sanak M; Dahlén SE; Woszczek G Allergy; 2022 Aug; 77(8):2337-2354. PubMed ID: 35174512 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]